Alimera Sciences, Inc. announced the appointment of Jason Werner, Chief Operating Officer (?COO?), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera?s Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations. Mr. Werner has served as a director of Alimera since Second Quarter 2023.

Prior to joining Alimera?s management team he has served as the Chief Executive Officer and Board Member of SightStream Biotherapeutics Inc, a biotechnology company focused on developing regenerative medicines in ophthalmics. Mr. Werner also currently serves on the board of directors of InflammX Therapeutics Inc, a privately held developer of novel treatments of the Inflammasome (NLRP3) Pathway based in San Diego, California. Mr. Werner previously co-founded and served as Chief Operating Officer of Eyevance Pharmaceuticals through its sale to Santen Pharmaceuticals Ltd. He has held a variety of commercial development roles and corporate strategy positions at companies such as Sun Pharma, Nicox SA and Inspire Pharmaceuticals, all within the field of ophthalmics.

Mr. Werner received his B.S. in business administration from the University of New Hampshire.